Should we tolerate tolerability as an objective in early drug development?
Cohen
A
A
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010601:Pharmacology, Clinical / Q000379:methods*; D017410:Practice Guidelines as Topic
D004364:Pharmaceutical Preparations
J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1509-15
11185674
Eur J Clin Pharmacol. 2000 May;56(2):167-74
10877012
Int J Cardiol. 2003 Sep;91(1):107-9
12957739
BMJ. 2003 Nov 22;327(7425):1222-5
14630763
Arzneimittelforschung. 1985;35(5):781-3
4026898
J Clin Pharmacol. 1995 Oct;35(10):957-66
8568013
J Pharm Sci. 1997 Jul;86(7):808-12
9232521
Br J Clin Pharmacol. 1997 Nov;44(5):477-86
9384465
Br J Clin Pharmacol. 1997 Nov;44(5):487-93
9384466
Am Heart J. 1998 May;135(5 Pt 1):797-804
9588408
Am J Cardiol. 1998 Aug 27;82(4B):18J-25J
9737642
Eur J Clin Pharmacol. 1998 Jul;54(5):443-7
9754991
Clin Pharmacokinet. 2006;45(1):77-84
16430312
Cerebrovasc Dis. 2006;21(4):279-93
16449807
BMJ. 2006 Mar 25;332(7543):677-8
16554332
BMJ. 2006 Apr 15;332(7546):870
16613944
Lancet. 2006 Oct 14;368(9544):1387-91
17046471
Br J Clin Pharmacol. 2007 Jul;64(1):75-82
17391323
Br J Clin Pharmacol. 2007 Sep;64(3):304-16
17367495
Br J Clin Pharmacol. 2007 Sep;64(3):397-8; author reply 398-9
17381477
Br J Clin Pharmacol. 2007 Sep;64(3):396-7; author reply 398-9
17381478
Br J Clin Pharmacol. 2007 Sep;64(3):292-303
17506785
Circulation. 1997 Jul 1;96(1):192-201
9236434
Neurology. 2000;55(11 Suppl 4):S51-2; discussion S53-6
11147510